Fecal eosinophil-derived neurotoxin rises with active pediatric EGID

Children with eosinophilic gastrointestinal diseases outside the esophagus often face a monitoring burden that reaches beyond symptoms alone. Repeated endoscopy remains central to confirming activity, yet the procedure is invasive, resource-intensive, and especially difficult to repeat in pediatrics. In this single-center retrospective case series, fecal eosinophil-derived neurotoxin (EDN) emerged as a candidate biomarker that moved in step with disease activity in children with predominantly non-esophageal EGID.

The cohort was small, but the signal was striking. Six children with EGID were followed between January 2012 and October 2025, with fecal EDN assessed during symptomatic active disease and again during asymptomatic remission, both phases verified endoscopically. Active-phase samples were also compared with those from 12 children with inflammatory bowel disease, including 5 with ulcerative colitis and 7 with Crohn’s disease. The design does not claim broad generalizability; it does, however, address a real bedside problem: how to track mucosal eosinophilic inflammation without sending a child repeatedly back to endoscopy.

A single marker cannot replace tissue, but it can sometimes reduce the need for it.

EDN separated active disease from remission and from inflammatory bowel disease

The most immediate finding was the magnitude of the difference between active EGID and remission. Median fecal EDN was 579,500 ng/mL during active disease and 2,250 ng/mL in remission, with a p value of 0.0312. That gap is large enough to suggest that the biomarker is capturing more than nonspecific gastrointestinal upset. EDN is released by activated eosinophils, so elevated stool levels fit the biology of EGID, where eosinophilic infiltration and degranulation drive mucosal injury, abdominal symptoms, and sometimes feeding problems or diarrhea depending on the site involved.

Compared with inflammatory bowel disease, active-phase fecal EDN was higher in EGID than in ulcerative colitis (p = 0.0087) and Crohn’s disease (p = 0.0012). The comparison matters because stool biomarkers in pediatrics are often interpreted through the lens of IBD, where fecal calprotectin has become familiar. EDN appears to be measuring a different inflammatory axis: eosinophil activation rather than the neutrophil-dominant inflammation typical of classic IBD. In practical terms, a child with persistent symptoms and a very high fecal EDN could be signaling eosinophil-driven disease even when standard inflammatory thinking might pull the clinician toward other diagnoses.

Treatment response moved in parallel with the biomarker

Longitudinally, fecal EDN fell in parallel with corticosteroid or dietary treatment in every patient. This is the part of the dataset that gives the biomarker its clinical appeal. A marker that only distinguishes one disease from another is interesting; a marker that declines when therapy is working is more useful at the bedside. Steroids suppress eosinophilic inflammation, and dietary elimination can remove the antigenic trigger in selected EGID phenotypes. The biomarker response therefore fits both the immunologic mechanism and the therapeutic logic of the disease.

The study also tested whether fecal EDN tracked blood eosinophils or a symptom-based score adapted from the Japanese clinical guideline. The answer was mixed. In exploratory pooled analyses, fecal EDN showed only a weak correlation with peripheral eosinophil count (Spearman’s ρ = 0.1347 across 192 measurements) and a modest correlation with the EGID symptom score (ρ = 0.3416 across 193 measurements). Those values suggest that stool EDN is not simply a proxy for circulating eosinophilia. Blood eosinophil counts can remain imperfect mirrors of tissue disease activity, especially when inflammation is localized to the gut. A fecal marker may therefore provide a more direct readout of the mucosal compartment than the peripheral bloodstream can offer.

What the findings can and cannot support

The study was retrospective, single-center, and limited to six children with EGID. Those boundaries are important. Small case series can reveal biologic plausibility and generate a testable monitoring strategy, but they cannot establish performance characteristics such as sensitivity, specificity, or clinical cutoffs. They also cannot determine whether fecal EDN can safely reduce the frequency of endoscopy, guide step-down therapy, or detect relapse before symptoms worsen.

Even so, the direction of the findings is hard to ignore. EDN was high during symptomatic disease, low during remission, and responsive to treatment. The biomarker also outperformed a simple blood eosinophil readout in terms of concordance with gut activity, though the correlations remained far from perfect. For clinicians managing children with non-esophageal EGID, that combination raises a realistic possibility: stool-based monitoring may eventually help separate persistent eosinophilic inflammation from lingering abdominal complaints or nonspecific gastrointestinal symptoms.

Because the article focused on pediatric EGID, the next step is not speculation about broad allergy use. The next step is validation in larger prospective cohorts, with standardized symptom instruments, predefined sampling windows, and direct comparison against endoscopic and histologic activity. Only then can fecal EDN be judged as a monitoring tool rather than an intriguing laboratory signal. For now, it stands as a biologically coherent marker that tracked disease activity in a rare pediatric disorder where every avoided endoscopy would matter.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Frontiers in Immunology.